Gene: SPTLC1
Official Full Name: serine palmitoyltransferase long chain base subunit 1provided by HGNC
Gene Summary: This gene encodes a member of the class-II pyridoxal-phosphate-dependent aminotransferase family. The encoded protein is the long chain base subunit 1 of serine palmitoyltransferase. Serine palmitoyltransferase converts L-serine and palmitoyl-CoA to 3-oxosphinganine with pyridoxal 5'-phosphate and is the key enzyme in sphingolipid biosynthesis. Mutations in this gene were identified in patients with hereditary sensory neuropathy type 1. Alternatively spliced variants encoding different isoforms have been identified. Pseudogenes of this gene have been defined on chromosomes 1, 6, 10, and 13. [provided by RefSeq, Jul 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO07687 | SPTLC1 Knockout cell line (HeLa) | Human | SPTLC1 | 1:3~1:6 | Negative | Online Inquiry |
KO07688 | SPTLC1 Knockout cell line (HCT 116) | Human | SPTLC1 | 1:2~1:4 | Negative | Online Inquiry |
KO07689 | SPTLC1 Knockout cell line (HEK293) | Human | SPTLC1 | 1:3~1:6 | Negative | Online Inquiry |
KO07690 | SPTLC1 Knockout cell line (A549) | Human | SPTLC1 | 1:3~1:4 | Negative | Online Inquiry |
SPTLC1 Gene Knockout Cell Lines consist of genetically engineered cell models designed to harbor a specific knockout of the serine palmitoyltransferase long-chain base subunit 1 (SPTLC1) gene. This gene plays a critical role in the biosynthesis of sphingolipids, which are essential components of cellular membranes and signaling pathways. The knockout mechanism typically employs CRISPR-Cas9 technology, resulting in the disruption of the gene's function. Consequently, these cell lines serve as invaluable tools for studying the effects of sphingolipid metabolism on various biological processes, including inflammation, apoptosis, and neurodegenerative diseases.
In research settings, SPTLC1 Gene Knockout Cell Lines are pivotal for investigating the cellular dynamics of sphingolipid-related disorders and metabolic pathways. Their application extends to drug discovery, wherein researchers can employ these models to evaluate the efficacy and safety of potential therapeutic agents targeting sphingolipid metabolism. Furthermore, they exhibit relevance in exploring the molecular mechanisms underpinning conditions such as multiple sclerosis, diabetes, and cancer.
What sets SPTLC1 Gene Knockout Cell Lines apart from conventional cell models is their specificity and precision; the targeted knockout approach provides a clearer understanding of the SPTLC1 gene's functions. Additionally, these cell lines enable researchers to perform robust correlation studies between sphingolipid composition and various physiological or pathological states. This precision ultimately leads to more reliable experimental outcomes, making them a preferred choice for cutting-edge research.
Using SPTLC1 Gene Knockout Cell Lines can significantly expedite the translation of findings from the bench to the clinic, providing researchers and clinicians with a powerful platform for investigating therapeutic interventions in sphingolipid-related diseases. Our company is dedicated to advancing research by offering high-quality, innovative biological products that meet the rigorous demands of modern scientific inquiry, ensuring that your research endeavors are supported by robust and reliable tools.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.